thought call
better outlook sure wait i/o dust settl set
merck admittedli look better expect enough us
get construct stock quit yet clinic competit risk could still
cloud intermedi term outlook notabl known
posit trial magnitude/dur treatment effect result key
patient subpopul unknown well rel benefit vs
impow forthcom merck deserv credit hit
first interim think limit near-term margin improv earn
acceler due legaci portfolio also need consid later-stag
non-i/o pipelin wont reach critic mass verubecestat prodrom
alzheim maintain equal weight pt
focu import reinforc keytruda monotherapi
merck could present earli chicago april clarifi
keytruda perform patient lack high express whether
overal surviv trend replic howev monotherapi
trial somewhat overlook success os primari endpoint
could reinforc keytruda role addit patient especi low express
ineligible/intoler combin therapi
demur deal pipelin play merck didnt signal shift biz dev
strategi note plan invest next five year capit project
recogn import invest infrastructur would prefer see
pipelin deal could firm long-term revenu growth pictur
model chang weve rais sale near
midpoint guidanc keytruda estim vs primarili due
better ou sale growth fx op ex expect grow result neg
oper leverag ep increas due lower tax rate
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight still i/o leader
nsclc revis clinic regulatori timelin
reduc merck abil acceler sale
earn growth intermedi term
make expand current multipl challeng
clinic risk remain concentr pipelin
asset could necessit find
faster uptak keytruda nsclc i/o
combin data acceler develop
preserv market share de-risk pipelin
posit pipelin data could put upward bia
consensu estim re-rat stock
continu weak core brand like remicad
januvia coupl faster share declin
keytruda pipelin setback could depress
revenu estim forward multipl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg million except per share itemspriorcurrentchg chg incom net item net ep ep ep ep outstand outstand analysispriorcurrentchg chg bp gross tax growthpriorcurrentchg chg barclay merck co
geoff meacham ph paul choi herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli
indirectli relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
